A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Actinic Keratoses
Interventions
DRUG

PEP005 (ingenol mebutate) Gel

two day treatment

DRUG

Vehicle gel

two day treatment

Trial Locations (17)

23507

Virginia Clinical Research, Inc, Norfolk

24501

The Education and Research Foundation, Lynchburg

30022

Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta

45220

Group Health Associates, Cincinnati

46256

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

47713

Deaconess Clinic Downtown, Evansville

60005

Altman Dermatology Associates, Arlington Heights

60089

Glazer Dermatology, Buffalo Grove

68144

Skin Specialists, PC, Omaha

71913

Burke Pharmaceutical Research, Hot Springs

75703

Dermatology Associates of Tyler, Tyler

77056

Suzanne Bruce and Associates, PA, The Center for Skin Research, Houston

78229

Dermatology Clinical Research Center of San Antonio, San Antonio

78759

DermResearch, Inc., Austin

84124

Dermatology Research Center, Inc., Salt Lake City

89002

Karl G. Heine Dermatology, Henderson

92117

Skin Surgery Medical Group Inc., San Diego

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00942604 - A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations | Biotech Hunter | Biotech Hunter